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Transformation of human embryonic stem cells (hESC) is of interest to scientists who use them as a raw
material for cell-processed therapeutic products. However, the WHO and ICH guidelines provide only
study design advice and general principles for tumorigenicity tests. In this study, we performed in vivo
tumorigenicity tests (teratoma formation) and genome-wide sequencing analysis of undifferentiated
hESCs i.e. SEES-1, -2 and -3 cells. We followed up with teratoma formation histopathologically after
subcutaneous injection of SEES cells into immunodeﬁcient mice in a qualitative manner and investigated
the transforming potential of the teratomas. Maturity of SEES-teratomas perceptibly increased after long-
term implantation, while areas of each tissue component remained unchanged. We found neither
atypical cells/structures nor cancer in the teratomas even after long-term implantation. The teratomas
generated by SEES cells matured histologically over time and did not increase in size. We also analyzed
genomic structures and sequences of SEES cells during cultivation by SNP bead arrays and next-
generation sequencing, respectively. The nucleotide substitution rate was 3.1  109, 4.0  109, and
4.6  109 per each division in SEES-1, SEES-2, and SEES-3 cells, respectively. Heterozygous single-
nucleotide variations were detected, but no signiﬁcant homologous mutations were found. Taken
together, these results imply that SEES-1, -2, and -3 cells do not exhibit in vivo transformation and
in vitro genomic instability.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Human embryonic stem cells (hESCs) have unique properties
such as their pluripotent differentiation potential and immortalitye Biology, National Research
kura, Setagaya, Tokyo,
494 7048.
A. Umezawa).
se Society for Regenerative
ative Medicine. Production and ho[1,2]. This capability to become a series of somatic cell types within
the human body garnered signiﬁcant attention and interest in the
ﬁelds of regenerative medicine. The ﬁrst clinical trial of hESC-based
therapy started with injection of a glial cell product into patients
with subacute spinal cord injury [3]. hESC-derived retinal pig-
mented epithelium was then developed for patients with Star-
gardt's macular dystrophy and dry age-related macular
degeneration [4,5]. Because hESCs are used as a raw material of
these cell-based products, the residual undifferentiated hESCs in
the ﬁnal products need to be examined for in vivo tumorigenicity
[6]. Using conventional assays, malignant transformationsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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hESC-teratomas has not yet been reported. When designing
tumorigenicity assays, important parameters to examine include
characterization of the transplanted stem cells, quantiﬁcation of the
number of engrafted cells, the mode and site of transplantation,
monitoring of tumor formation and growth, and pathological
analysis [7]. Monitoring teratomas as such is crucial, since theo-
retically, hESC-derived cells survive over time.
Genomic mutations may arise in hESC-derived cells during
cultivation, posing an additional risk for their clinical use. Karyo-
typic analysis and comparative genomic hybridization (CGH) are
commonly used to detect chromosomal and sub-chromosomal
aberrations. Genome-wide sequencing analysis has also been
applied to monitor cells in this context [8,9]. Mutation rates have
been determined by various methods in human cells [10e12], and
genomic sequence of hESCs has been monitored as an index for
transformation and for determining nucleotide substitution rates of
hESCs as compared with other cell types.
In this study, we monitored histoepathological parameters of
hESC-teratomas in vivo over time, and examined their genomic
alteratiosn. We found that hESC-teratomas histologically matured
over time, and that the nucleotide substitution rate in hESCs was
comparable with that of somatic cells.
2. Results
Tests to detect malignant transformations include tumorige-
nicity test by subcutaneous implantation to immunodeﬁcient mice.
In addition to these tests, “genetic abnormality that induces
persistent cell proliferation” and “genomic instability” are addi-
tional concerns. From the viewpoints of tumorigenicity of ESCs
used as a starting material for manufacturing of regenerative
medicine products, we herewith investigated teratoma analysis by
subcutaneous implantation of SEES cells and genome-wide anal-
ysis, i.e. CGH and whole exome analysis to detect the transforming
activity of the SEES cells.
2.1. Teratoma formation of SEES cells
To address whether the SEES cells (SEES-1, -2 and -3) have the
competence to differentiate into speciﬁc tissues, teratomas were
formed by subcutaneous implantation of SEES cells (1.0  107 cells⁄
site) into immunodeﬁcient mice (Fig. 1). Three independent clones
of SEES cells induced teratomas within 6e10 weeks after implan-
tation. Histological analysis of parafﬁn-embedded sections
demonstrated that the three primary germ layers were generated
as shown by the presence of ectodermal epidermis, glomerulus-like
structure, retina, retinal pigmented epithelium, ganglion and neu-
roepithelium, mesodermal muscle and cartilage, and endodermal
ciliated epithelium, proper gastric glands and hepatocytes in the
teratomas. Thus, all SEES cell clones examined had potential for
multi-lineage differentiation in vivo. We did not detect germ cell
tumors, sarcomas or carcinomas in SEES-derived teratomas by
histopathological analysis [13].
2.2. Morphometric analysis of teratomas
To investigate the predisposition of SEES cells to differentiate
in vivo, we measured the areas of histological components such as
cartilage, epidermis and intestine (Fig. 2AeE). The ratios of each
component did not differ among teratomas generated by SEES-1, -2,
and -3 cells (Fig. 2FeH). We also performed the same experiments
using SEES cells at different PDs, i.e. short- and long-term cultiva-
tion, to investigate whether long-term cultivation affects in vivodifferentiation (Fig. 3). The in vivo differentiation of SEES cells was
independent of the cultivation period or passage number.
2.3. Long-term observation of teratomas generated by SEES cells
We followed up the teratomas generated by SEES cells for up to
32 weeks (Fig. 4). The maturity of hESC-teratomas clearly increased
after long-term implantation, while the total area made up of each
component remained unchanged. Epidermal cysts and intestines
included keratinous and secretory material, respectively, and the
cyst and intestinal lumen became enlarged due to accumulation of
the keratinous and secretory material (Fig. 4GeJ). We found neither
atypical cell/structure nor cancer in the teratomas after long-term
implantation.
2.4. Structural alteration analysis and exome analysis in hESCs
We performed CGH with the dye swap method on the SEES cell
lines to investigate whether they had structural alterations (Fig. 5A,
B). Compared to each hESC line at an early passage, we detected no
chromosomal aberrations, including gain and loss, in all stocks of
hESC lines (SEES-1, -2, -3). We then performed whole exome
sequence analysis on the SEES cell lines to clarify the number of
genetic alterations that occurred during cultivation (Fig. 5CeF). The
exome analysis targeted 93.91 Mb in the genome; 21.78 Mb func-
tion as protein-coding sequences and start or stop codons (Fig. 5C).
This exome study also covered a large part of the non-coding DNA
sequences (non-CDS). Mapping to the reference genomic sequence
hs37d5, single-nucleotide variations (SNVs) and small indels were
detected at two different passages (Fig. 5D). Subsequently, the two
identiﬁed genotypes at earlier and later passages were compared to
ﬁnd the de novo mutations occurred during the cell culture period.
Because platform-speciﬁc or method-speciﬁc errors are offset in
this process, reliable mutation data can be obtained. In the initial
analysis of the SEES-1 line, 325 single-nucleotide and 69 indel
mutations had been identiﬁed. When each genotype was exam-
ined, we noticed that a chromosome-wide mutational event
causing loss of heterozygosity (LOH) occurred on the X chromo-
some. Hence, we also performed a structural alteration analysis by
using a SNP genotyping array for all the samples. In contrast to CGH,
it can also detect copy-neutral LOHwith higher resolution. In SEES-
1, the sole detected mutation was a deletion of one of the two X
chromosomes after passage 10. Most of hetero-to-homo genotype
calls on the chromosome turned out to be caused by the chromo-
somal deletion rather than single-nucleotide mutations. We
excluded such calls and instead calculated the mutation rate of
single-nucleotide substitutions. Under our cultivation conditions,
one passage corresponds to approximately three population dou-
blings (PDs). In total, 99 single bases mutated during 168 PDs in the
diploid sequences of the exome targets, i.e. 3.1  109 mutations
per site per PD. The numbers of mutations of SEES-2 during pas-
sages 4 and 45 were 93 single-nucleotide and 18 indel mutations
(Fig. 5E). Those found in SEES-3 during passages 4 and 24 were 52
and 12 mutations, respectively. No structural mutations were
detected by SNP array in the SEES-2 and SEES-3 lines. Similarly, the
mutation rates of SEES-2 and SEES-3 were calculated as 4.0  109
and 4.6  109, respectively. The regional annotation of single-
nucleotide mutations shows that the number of non-synonymous
bases is larger than that of synonymous bases (Fig. 5F).
We also investigated whether SEES-2 cells have mutations in
cancer-related genes that are listed in the literature [14]
(Supplemental Table 1). We did not ﬁnd any signiﬁcant homozy-
gous nonsynonymous genetic alterations of the above-mentioned
cancer-related genes in the SEES-2 cells used for teratoma
formation.
Fig. 1. In vivo pluripotency of SEES cells. A. Low power view of teratoma. B. Epidermis with keratinization. C. Glomerulus-like structure (quasi-glomerulus). D. Proper gastric glands.
E. Hepatocytes. F. Ganglion. G. Tracheobronchial tissue-like structure with ciliated epithelium and glands. H. Cartilage and bone. I. Glandular structure (quasi-pancreas). J. Immature
neuroepithelium. K and L. Hair follicles K: low-power view, L: high-power view. M. Retina and retinal pigmented epithelium.
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Fig. 2. Morphometric analysis of teratoma. A. Hematoxylin and eosin stain of teratoma. B. Morphometric analysis of teratoma. Total area: (area deﬁned by black lines) minus (cystic
area deﬁned by yellow lines), cartilage: area deﬁned by blue lines, epidermis: area deﬁned by green lines, intestine: area deﬁned by orange lines. C. Representative image of cartilage
as deﬁned by blue lines in panel B. D. Representative image of epidermis as deﬁned by green lines in panel B. E. Representative image of intestine as deﬁned by orange lines in panel
B. F. Percentage of cartilage area in teratomas generated by each hES cell. Values between the indicated hES cell lines were statistically insigniﬁcant with p < 0.01 by Student's t-test
(SEES-1 versus SEES-2, p ¼ 0.39; SEES-1 versus SEES-3, p ¼ 0.15; SEES-2 versus SEES-3, p ¼ 0.10). G. Percentage of epidermis area in teratomas generated by each hES cell. Values
between the indicated hES cell lines were statistically insigniﬁcant with p < 0.01 by Student's t-test (SEES-1 versus SEES-2, p ¼ 0.23; SEES-1 versus SEES-3, p ¼ 0.76; SEES-2 versus
SEES-3, p ¼ 0.13). H. Percentage of intestine area in teratomas generated by each hES cell. Values between the indicated hES cell lines were statistically insigniﬁcant with p < 0.01 by
Student's t-test (SEES-1 versus SEES-2, p ¼ 0.20; SEES-1 versus SEES-3, p ¼ 0.38; SEES-2 versus SEES-3, p ¼ 0.56).
H. Akutsu et al. / Regenerative Therapy 5 (2016) 31e39343. Discussion
3.1. Do SEES teratomas mature over time?
It is not surprising that SEES teratoma included mature tissues,
i.e. epidermis, retina, retinal pigmented epithelium, cartilage, cili-
ated epithelium, proper gastric glands and hepatocytes, as well as
immature neural tissue regardless of the SEES cell lines used. The
unchanged histological component ratio of ectodermal, meso-
dermal, and endodermal origins in the teratomas after long-term
in vitro replication of SEES cells, i.e. more than 100 PDs, clearly
indicates maintenance of multipotency of hESCs with immortality
under the appropriate cultivation conditions. It is noteworthy thatSEES teratomas often included immature glomeruli that are rarely
seen in human teratoma. Lack of atypical cells/cancer cells in SEES
teratoma is also not surprising because hESCs are considered intact
cells that are not infected by exogenous genes such as oncogenes,
unlike induced pluripotent stem cells [15e17]. Histological diag-
nosis of the tumors generated by SEES cells was, in all cases,
immature teratoma [13,18]. Immature teratoma is typically malig-
nant and is more often found in men, while an immature teratoma
in children often behaves like a benign tumor. It is thus one of in-
terest in this study whether SEES teratomas show maturity or
immaturity during long-term implantation. SEES teratoma indeed
exhibited in vivo maturation, including neural tissue. The in vivo
maturation of SEES teratoma over time is preferable when SEES
Fig. 3. Effect of long cultivation of hESCs on component area of teratoma. SEES-2 cells at population doublings (PD) 21 and PD 104, and SEES-3 cells at PD 18-33 and PD 104-111
were implanted to generate teratomas. Histological components of teratomas were morphometrically analyzed as described in Materials and Methods and in the legend for Fig. 2. A.
Percentage of cartilage area in teratomas generated by SEES-2 cells. Values between PD 21 and PD 104 were statistically insigniﬁcant with p < 0.01 by Student's t-test (p ¼ 0.28). B.
Percentage of cartilage area in teratomas generated by SEES-3 cells. Values between PD 18-33 and PD 104-111 were statistically insigniﬁcant with p < 0.01 by Student's t-test
(p ¼ 0.24). C. Percentage of epidermis area in teratomas generated by SEES-2 cells. Values between PD 21 and PD 104 were statistically insigniﬁcant with p < 0.01 by Student's t-test
(p ¼ 0.74). D. Percentage of epidermis area in teratomas generated by SEES-3 cells. Values between PD 18-33 and PD 104-111 were statistically insigniﬁcant with p < 0.01 by
Student's t-test (p ¼ 0.18). E. Percentage of intestine area in teratomas generated by SEES-2 cells. Values between PD 21 and PD 104 were statistically insigniﬁcant with p < 0.01 by
Student's t-test (p ¼ 0.32). F. Percentage of intestine area in teratomas generated by SEES-3 cells. Values between PD 18-33 and PD 104-111 were statistically insigniﬁcant with
p < 0.01 by Student's t-test (p ¼ 0.63).
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erative medicine. Residual undifferentiated ESCs during generation
of cellular and tissue-based products are expected to remain benign
after implantation.
3.2. Subchromosomal analysis of hESC genome
To investigate genomic alterations in cellular and tissue-based
products, karyotypic analysis has been used because it is one of
the most trustworthy methods. In addition to karyotypic analysis,
we also utilized CGH analysis for determining the genomic stability
of hESCs [19]. CGH analysis can be used for a genetically homoge-
neous population that has been generated by predominant prolif-
eration or when the cultivation procedure includes subcloning ofcells. Proliferating hESCs are usually passaged by choosing several
single colonies, and is thus applicable to CGH analysis. From the
viewpoint of genetic validation for regenerative medicine, CGH
analysis may soon dominate because it is inexpensive, fast and
simple.
3.3. Comparable mutation rate in hESCs
Mutation rate per nucleotide has been estimated in human cells
per generation [20], in human somatic cells [11], and during the
reprogramming of human somatic cells into iPSCs [21]. Different
methods have been applied to determine mutation rate as
sequence techniques have been dramatically developing. For this
reason, it is difﬁcult to simply compare mutation rate in cells and
Fig. 4. In vivo maturation of SEES teratoma. A. Teratoma at 17 weeks after implantation of SEES-3 cells. B, C. Teratomas at 31 weeks after implantation of SEES-3 cells. D, E, F.
Teratomas at 32 weeks after implantation of SEEDS-3 cells. G. High power view of intestinal epithelium (inlet in panel D). Dashed line: the intestinal lumen became enlarged due to
accumulation of the mucus. H. High power view of intestinal epithelium (inlet in panel G). Note that intestinal epithelium were fully differentiated. I. High power view of epidermis
with prominent keratinization (inlet in panel E). Dashed line: the epidermal cyst became enlarged due to accumulation of the keratinizing material. J. High power view of epidermis
with distinct 4 layers, i.e. basal, spinous, granular, and horny layers (the inlet in panel I).
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rate in hESCs as well. Whole exome analysis was used to estimate
mutation rate in hESCs in this study because of its inexpensiveness
and straightforwardness. The mutation rate of SEES-1 may beunderestimated by the deletion of the X chromosome. Because
number of passages for the SEES-3 was relatively small, the margin
of error could be larger than those of SEES-1 and SEES-2. In any
case, the mutation rates calculated from the three SEES lines were
Fig. 5. Comparative genomic hybridization (CGH) in SEES cell cultivation. A. Scheme of CGH analysis. B. CGH analysis between SEES-4 cells at Passage (P) 8 and 22. C. Exome
analysis of SEES cells Pie chart illustrates the ratio of protein-coding and non-coding bases. Our exome analysis targeted 93.908 Mb in the genome; 21.780 Mb out of them
function as part of coding DNA sequences, start or stop codons, indicated as CDS in the ﬁgure. The present exome study covers a large part of non-coding DNA sequences (non-
CDS). D. Flow chart showing each step of the exome analysis. Program names used in the present study are parenthesized. FASTQ ﬁles of sample 1 and sample 2 were
separately processed and converted to BAM ﬁles. Variants, in other words, SNVs and indels, were called by comparison to the human reference genome (hs37d5). De novo
mutations caused during the ESC culture were detected by subtraction of called variants in sample 2 and sample 1. Because platform-speciﬁc errors were offset, relatively
accurate data were obtained. Variants found in a structural mutation, such as deletion, copy-number gain, and copy-neutral LOH, were removed for the mutation counting. E.
Genome-wide distribution of the mutations identiﬁed in the SEES-2 exome analysis. Filled squares above each chromosomal bar stand for genomic positions of mutations.
Green, blue, and red squares indicate single-nucleotide substitution, short insertion, and short deletion, respectively. F. Regional annotation of single-nucleotide mutations
caused during the SEES-2 culture (41 passages). Note that the number of non-synonymous bases is larger than that of synonymous bases. Annotations were performed using
ANNOVAR.
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comparable with what is reported for human somatic mutation
rates. Numbers of small-scale indel mutations detected by the
present methods were much smaller than those of single-
nucleotide substitution mutations. Only a few large-scale struc-
tural mutations were detected by CGH and SNP array in the present
study, suggesting genetic stability of these ES cell lines.
3.4. Tumorigenicity of undifferentiated ESCs as a starting material
for regenerative medicine products/cellular and tissue-based
products
Undifferentiated ESCs remaining in ﬁnal products after
manufacturingmay produce teratomas in patients and be related to
increased tumorigenicity. Although it is difﬁcult to completely
eliminate a risk of transformation, in this study, we revealed the
low risk of human ESCs by a qualitative follow-up study of tera-
tomas by genomic structure and sequence analysis. Effort should be
made to investigate, estimate and reduce the risk of tumorigenicity
by use of currently available means to a reasonable extent [22].
4. Materials and methods
4.1. hESC culture
The ethics committee of the NCCHD speciﬁcally approved this
study. The derivation and cultivation of hESC lines were performed
in full compliance with “the Guidelines for Derivation and Distri-
bution of Human Embryonic Stem Cells (Notiﬁcation of the Min-
istry of Education, Culture, Sports, Science, and Technology in Japan
(MEXT), No. 156 of August 21, 2009; Notiﬁcation of MEXT, No. 86 of
May 20, 2010) and “the Guidelines for Utilization of Human Em-
bryonic Stem Cells (Notiﬁcation of MEXT, No. 157 of August 21,
2009; Notiﬁcation of MEXT, No. 87 of May 20, 2010)”. Human ESCs,
i.e. SEES-1, -2, and -3, were used in this study. SEES lines were
routinely cultured onto a feeder layer of freshly plated gamma-
irradiated mouse embryonic ﬁbroblasts, isolated from ICR em-
bryos at 12.5 gestations and passages 2 times before irradiation
(30 Gy), in the hESC culture media. The hESC media consisted of
Knockout™-Dulbecco's modiﬁed Eagle's medium (KO-DMEM) (Life
Technologies, CA, USA; #10829-018) supplemented with 20%
Knockout™-Serum Replacement (KO-SR; #10828-028), 2 mM
Glutamax-I (#35050-079), 0.1 mM non-essential amino acids
(NEAA; #11140-076), 50 U/ml penicillin-50 mg/ml streptomycin
(Pen-Strep) (#15070-063), 0.055 mM beta-mercaptoethanol
(#21985-023) and recombinant human full-length bFGF
(#PHG0261) at 10 ng/ml (all reagents from Life Technologies). Cells
were expanded using STEMPRO® EZPassage™ (#23181010)/glass
capillaries manually, or enzymatic passaging by Dispase II (Eidia,
Ibaraki, Japan; #GD81070) [1,23].
4.2. Teratoma formation
Pluripotency in vivo was assessed by teratoma formation in
immunodeﬁcient nude mice (BALB/cAJcl-nu/nu; CLEA Japan Inc.
Tokyo, Japan). A 60mmplate of undifferentiated hESCs was washed
with phosphate-buffered saline (PBS) (Life Technologies, #14190-
250) and the cells were harvested with a cell scraper. The cell
suspension was collected into a 15-ml conical tube and spun down
at 1000 rpm for 4 min. The cell pellet was resuspended by addition
of a 1:1 mixture of hESC culture medium and Matrigel (BD Bio-
sciences, NJ, USA #356234) to a ﬁnal total volume of 400 ml.
Approximately 2e5  106 cells in 200 ml/injection site were injec-
ted in the dorsolateral area into the subcutaneous space on both
sides. Tumors were excised surgically. The total number of samplesfor SEES-1, SEES-2, and SEES-3 were 7, 5, and 26, respectively. The
animal use protocol was approved by the Institutional Animal Care
and Use Committee according the National Research Institute for
Child Health and Development (NRICHD, Permit Number: A2003-
002). All experiments with mice were subject to the 3 R consider-
ation (reﬁne, reduce replace) and all efforts weremade tominimize
animal suffering, and to reduce the number of animals used.
4.3. Histological analysis
The tumor-containing tissues were ﬁxed in 4% para-
formaldehyde (PFA), embedded in parafﬁn and serially sectioned
into 5 micron sections. Every other section was mounted on slides
(2e10 slides for each tumor). Various parts of the tumor were
stained with hematoxylin and eosin (HE), and subjected to histo-
logical analysis by certiﬁed pathologists. Large tumors were cut in
half before ﬁxation, and each of the two halves were placed in the
parafﬁn block so that the central parts of tumor (with the larger
surface area) were face up. To enable analysis of the different parts
of large tumors, the sectioning was performed from the upper part
of the parafﬁn block, containing the central parts of both halves of
the tumor, towards the tumor's edges. The micoscopic images of
teratomas were digitally marked by the pen tool of the Aperio
ImageScope software (version 11.2.0.780). The area was automati-
cally calculated after marking.
4.4. Array comparative genomic hybridization (aCGH)
To analyze genomic structural variants, we chose Agilent Sure-
Print G3 Mouse Microarray 8  60 K array technology for aCGH
analysis [19]. Test and reference genomic DNAs (250 ng per sample)
of human ESCs were ﬂuorescently labeled with Cy5 (test: passage 4
of SEES-2) and Cy3 (reference: passage 24 of SEES-2) with a
Genomic DNA Enzymatic Labeling Kit (Agilent Technologies). All
array hybridizations were performed according to the manufac-
turer's methods. All regions of statistically signiﬁcant copy number
change were determined using Aberration Detection Method-2
(ADM2) algorithms [24]. The ADM2 algorithms identify genomic
regions with copy-number differences between the test and the
reference based on log2 ratios of ﬂuorescent signals from probes in
the interval.
4.5. Exome sequencing
Approximately 2.0 mg of genomic DNA from each cell sample
was sonicated to give a fragment size of 200 bp on a Covaris S220
instrument. After 5e6 cycles of PCR ampliﬁcation, capture and li-
brary preparation were performed with Agilent SureSelect Human
All Exon V4 þ UTRs þ lincRNA (80 Mb), followed by washing,
elution, and additional 10-cycle PCR. Enriched libraries were
sequenced on an Illumina HiSeq 1000 operated in 101-bp paired-
end mode. Image analyses and base calling on all lanes of data
were performed using CASAVA 1.8.2 with default parameters.
4.6. Read mapping and variant analysis
Reads from each sample were ﬁrst trimmed by removing
adapters and low quality bases at ends using Trimmomatic 0.22 and
then aligned to the hs37d5 sequence (hg19 and decoy sequences)
using the Burrows-Wheeler Aligner 0.6.2. Uniquely mapped reads
were selected by a custom script, converted from sam to bam using
SAMtools 0.1.18, and processed by Picard 1.83 to remove PCR du-
plicates. Genome Analysis Toolkit (GATK) 2.4.9e3 was then used to
perform local realignment and map quality score recalibration to
produce calibrated bam ﬁles for each sample. Multi-sample calls for
H. Akutsu et al. / Regenerative Therapy 5 (2016) 31e39 39SNVs were made by GATK. The annotated VCF ﬁles were then
ﬁltered using GATK with a stringent ﬁlter setting and custom
scripts. Variant calls which failed to pass the following ﬁlters were
eliminated: QUAL <400 jj QD < 2.0 jj MQ < 40.0 jj FS > 60.0 jj
HaplotypeScore >13.0 jj GQ 60. When genotype is 0/1, 0/2, or 1/2,
only SNVs that meet the following conditions were selected: both
of the allelic depths  8 && difference of the allelic depths within
twofold. When genotype is 0/0, 1/1, or 2/2, only SNVs that meet the
following conditions were selected: difference of the allelic depths
no less than 32-fold, one allelic depth is 1 and the other is no less
than 16, or one allelic depth is 0 and the other is no less than 8.
Annotations of altered bases were made using ANNOVER based on
GRCh37 Custom Perl scripts and C programs are available at http://
github.com/glires/genomics/.
4.7. Structural mutation analysis
The structural mutation analysis by genome-wide SNP geno-
typing was performed using Illumina HumanCytoSNP-12 v2.1 DNA
Analysis BeadChip Kit. The microarray contains approximately
300,000 SNP markers with an average call frequency of >99%.
Subsequent computational and manual analyses were performed
using the Illumina KaryoStudio software.
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